Cell Signaling Technology

Product Pathways - Development

SPARC (D10F10) Rabbit mAb #8725

Applications Reactivity Sensitivity MW (kDa) Isotype
W IHC-P H M Endogenous 42 Rabbit IgG

Applications Key:  W=Western Blotting  IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key:  H=Human  M=Mouse
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

SPARC (D10F10) Rabbit mAb recognizes endogenous levels of total SPARC protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human SPARC protein.

Western Blotting

Western Blotting

Western blot analysis of culture medium, from SPARC-secreting PYS-2 cells, using SPARC (D10F10) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human colon carcinoma using SPARC (D10F10) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lung carcinoma using SPARC (D10F10) Rabbit mAb.


Background

SPARC (secreted protein acidic and rich in cysteine), also known as osteonectin and BM40, is a secreted matricellular glycoprotein that belongs to a group of functionally related glycoproteins that includes tenascins C and X, thrombospondins 1 and 2, and osteopontin (1). Members in this class of glycoproteins are involved in tissue renewal, tissue remodeling, and embryonic development and work by exerting counter-adhesive and antiproliferative effects that lead to changes in cell shape, disruption of cell adhesion, and inhibition of the cell cycle (2). SPARC is expressed at high levels in bone tissue but is widely distributed in many other tissues and cell types (3), and is known to be associated with tissues undergoing morphogenesis, angiogenesis, mineralization, and other pathological responses to injury and tumorigenesis (4,5). SPARC has also been linked with obesity and diabetes (6).

  1. Fukunaga-Kalabis, M. et al. (2008) Cancer Microenviron 1, 93-102.
  2. Yan, Q. and Sage, E.H. (1999) J Histochem Cytochem 47, 1495-506.
  3. Maillard, C. et al. (1992) Bone 13, 257-64.
  4. Sage, E.H. (1997) Nat Med 3, 144-6.
  5. Bradshaw, A.D. and Sage, E.H. (2001) J Clin Invest 107, 1049-54.
  6. Kos, K. and Wilding, J.P. (2010) Nat Rev Endocrinol 6, 225-35.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products